Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Sanofi : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi Therapeutic

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/20/2017 | 02:57pm CEST
   By Sonia Amaral Rohter 
 

Sanofi SA (>> Sanofi) and Alnylam Pharmaceuticals Inc. (>> Alnylam Pharmaceuticals, Inc.) reported Wednesday that Patisiran met all primary and secondary endpoints in a Phase III trial of its use against a rare, inherited disorder.

The trial looked at the use of Patisiran in patients with hereditary transthyretin-mediated amyloidosis, a progressively debilitating disease in which a gene mutation causes the production of a type of abnormal protein that accumulates in body organs and tissues, damaging them. Patisiran is designed to target and silence the mechanism that leads to production of this protein.

Patisiran is part of a class of medicines called RNA interference, or RNAi, therapeutics that aim to inhibit the expression of certain genes in order to treat or prevent disease.

Alnylam Chief Executive John Maraganore said: "We are very proud to report the first-ever positive Phase III results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines."

Alnylam said it would file a new drug application with the U.S. Food and Drug Administration in late 2017. Should the company receive regulatory approval, Alnylam will commercialize Patisiran in the U.S., Canada and Western Europe, while Sanofi Genzyme will commercialize the product in the rest of the world.

The full results of the trial will be presented on November 2.

Write to Sonia Amaral Rohter at [email protected]

Stocks mentioned in the article : Sanofi, Alnylam Pharmaceuticals, Inc.
Stocks mentioned in the article
ChangeLast1st jan.
ALNYLAM PHARMACEUTICALS, INC. 1.47% 104.2 Delayed Quote.-17.65%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
06/22SANOFI : completes its acquisition of Ablynx following the expiration of the Squ..
AQ
06/21SANOFI : Translate Bio Announces Agreement with Sanofi Pasteur to Develop Vaccin..
AQ
06/21SANOFI : completes $3.9bn acquisition of Ablynx
AQ
06/21EVOTEC : and Sanofi sign definitive agreement to combat infectious diseases
AQ
06/21LEXICON PHARMACEUTICALS : to Present New Clinical Data at 78th American Diabetes..
AQ
06/20SANOFI : New study on Dengvaxia ill-effects boosts demand for full refund
AQ
06/20SANOFI : Completes Its Acquisition of Ablynx Following Expiration of Squeeze-Out..
AQ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19SANOFI : Recipharm buys Sanofi CMO site in UK, signs long-term supply deal
AQ
06/19EVOTEC : and Sanofi Sign Definitive Agreement to Combat Infectious Diseases
AQ
More news
News from SeekingAlpha
06/19Translate Bio Prepares For $100 Million U.S. IPO 
06/19Merger Arbitrage Mondays - June 18, 2018 
06/19Sanofi transfers infectious disease unit to Evotec 
06/19Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice Presiden.. 
06/16STOCKS TO WATCH : Don't Sleep On Vienna 
Financials (€)
Sales 2018 35 273 M
EBIT 2018 8 334 M
Net income 2018 5 099 M
Debt 2018 15 707 M
Yield 2018 4,46%
P/E ratio 2018 16,29
P/E ratio 2019 15,22
EV / Sales 2018 2,86x
EV / Sales 2019 2,71x
Capitalization 85 320 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 77,0 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.93%99 211
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
MERCK AND COMPANY8.90%164 862